Hexima Ltd · ASX:HXL
Hexima — Share Cafe (April 2022)
17 slides from Hexima's conference presentation, April 2022
Slide 1: Hexima Limited (ASX:HXL) - Share Cafe
SHARE CAFE HEXIMA LIMITED (ASX:HXL) A game-changing treatment for onychomycosis 1
Slide 2: Disclaimer
DISCLAIMER Summary information events and the future financial performance of Hexima. Forward looking words such as “expect”, “should”, “could”, “may”, This presentation has been prepared by Hexima Ltd and its subsidiaries (collectively “Hexima”). The information in this “predict”, “plan”, “will”, “
Slide 3: Developing a novel topical product addressing a clear unmet need
HEXIMA LIMITED (ASX:HXL) D E V E LOP IN G A N OV E L T OP ICA L P ROD UCT A D D RE S S IN G A CLE A R UN M E T N E E D IN A L A RGE A N D GROWIN G M A RK E T CLINICAL-STAGE, LARGE AND GROWING NOVEL, PROPRIETARY PEZADEFTIDE ADDRESSES WELL-DEFINED INFECTIOUS DISEASE-FOCUSED MARKET WITH SUBSTANTIAL MOL
Slide 4: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM P ROV E N T RA CK RE CORD OF D E L IV E RIN G V A LUE MICHAEL ALDRIDGE DR. NICOLE VAN DER WEERDEN PROF. MARILYN ANDERSON DR NANCY SACCO PHILLIP ROSE Chief Executive Officer Chief Operating Officer Chief Science Officer Chief Development Officer Chief Commercial Officer CE
Slide 5: Pezadeftide in Action
PEZADEFTIDE IN ACTION Click to play animation C O N S U M ER- CENTRI C D E V EL O PM ENT S L I D E 5
Slide 6: Existing therapies do not meet consumer needs
EXISTING THERAPIES DO NOT MEET CONSUMER NEEDS CL E A R M A RK E T N E E D F OR A S A F E , CON V E N IE N T A N D M ORE E F F E CT IV E T OP ICA L P ROD UCT TOPICAL Long treatments, ORAL DRUGS Better efficacy but potential TREATMENTS poor efficacy for serious adverse events Patients with Patients of
Slide 7: Our Solution: Pezadeftide
OUR SOLUTION: PEZADEFTIDE A NATURALLY OCCURRING PEPTIDE PEZADEFTIDE MOLECULE IT S UN IQUE P ROP E RT IE S E N A BL E RA P ID N A IL P E N E T RA T ION A N D F UN GA L KILLIN G Pezadeftide is a potent broad-spectrum antifungal peptide that has evolved to kill fungal pathogens • Hydrophilic & highly s
Slide 8: Successful Phase I Clinical Trial
SUCCESSFUL PHASE I CLINICAL TRIAL 12 12 HXP124-ONY-001 – TRIAL DESIGN WEEKS WEEKS Randomised, double blind, vehicle- C OH ORT 3 C OH ORT 4 controlled, ascending dose cohort study Pezadeftide 2% Pezadeftide 2% N=6 patients N=30 patients Patients treated nails daily with (randomised 2:1) (randomised 4
Slide 9: Phase I: Primary Endpoint Safety and Tolerability
PHASE I: PRIMARY ENDPOINT SAFETY AND TOLERABILITY HX P 1 2 4 - ON Y - 0 0 1 – N O S Y S T E M IC A BS ORP T ION A N D N O LOCA L RE D N E S S OR IRRIT A T ION Pezadeftide is safe and well tolerated NOL OR D RE U MGIPS - R EULM ATED N NOO S Y S T E M IC IC A D V EDROL S EORE V E N T S TTO OXX IICIT C
Slide 10: Phase I: Effective and Rapid Anti-Fungal Activity
PHASE I: EFFECTIVE AND RAPID ANTI-FUNGAL ACTIVITY HXP124-ONY-001 – MYCOLOGICAL CURE RATE FOR COHORT 4 30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS Mycological Cure at 12 weeks 75.0% 69.0% Mycological cure* was achieved in 69% 60.0% of pezadeftide-treated nails in Cohort 4 within 12 weeks (vehic
Slide 11: Phase I: Rapid Clearance of Affected Nail Area
PHASE I: RAPID CLEARANCE OF AFFECTED NAIL AREA HXP124-ONY-001 – CLEAR NAIL GROWTH FOR COHORT 4 30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS Clinical Efficacy over time 15% 14% Pezadeftide cleared the affected nail Proportion of patients with area more effectively than vehicle <10% affected nail
Slide 12: Rapid and Dramatic Improvement in Appearance of Nails
RAPID AND DRAMATIC IMPROVEMENT IN APPEARANCE OF NAILS Click to play animation N OT ICE A BLE IM P ROV E M E N T IN J US T 2 WE E KS , A L M OS T CLE A R IN 1 2 W E E KS Pezadeftide penetrates the nail to kill the fungus, allowing healthy, uninfected nail to grow out • Clear nail growth continues aft
Slide 13: Potential to deliver the preferred solution in a consumer-driven market
POTENTIAL TO DELIVER THE PREFERRED SOLUTION IN A CONSUMER-DRIVEN MARKET Convenient, Effective, Safe, topical short course of best-in-class medication therapy mycological cure FOR PATIENTS WHO WANT FOR PHYSICIANS WHO WANT FOR PAYERS WHO WANT An easy-to-apply topical An effective product that will An
Slide 14: Phase II Clinical Trial
PHASE II CLINICAL TRIAL HX P 1 2 4 - ON Y - 0 0 2 Results Q2 2022 WEEK WEEK WEEK WEEK 13 24 36 40 • Multi-center, randomised, double blind, SHORT COURSE 12 WEEK DAILY DOSING vehicle-controlled study • Primary endpoint safety and tolerability, LOADING/PULSE 1 2 W E E K D A I L Y D O S I N G F O L L O
Slide 15: Phase II Clinical Trial - Results Q2 2022
PHASE II CLINICAL TRIAL – RESULTS Q2 P L A T F ORM T O A D V A N CE T O P HA S E III DEFINITION OF SUCCESS WEEK WEEK 36 0 PHASE I PHASE II COM PA RA BLE OR RESULTS Q2 2022 1 2 - 3 6 W E E KS DA ILY 6 - W E E K DA ILY D OS IN G BE T T E R M YCOLOGICA L 6 WEEKS DAILY DOSING D OS IN G CURE FOL LOW UP A
Slide 16: Pezadeftide: A potential solution for a large and poorly served market
PEZADEFTIDE: A POTENTIAL SOLUTION FOR A LARGE AND POORLY SERVED MARKET POORLY SERVED MARKET NEW AND UNIQUE SAFE CONVENIENT EFFECTIVE Affects 14% of the Novel molecule with No systemic effects Easy to apply Efficiently penetrates population unique mode of action the nail No local redness or Short tre
Slide 17: Contacts
CONTACTS MIC HAEL D R NIC OLE ALD RID GE VAN D ER WEERD EN CHIE F E X E CUT IV E OF F ICE R CHIE F OP E RA T IN G OF F ICE R m.aldridge@hexima.com.au n.vanderweerden@hexima.com.au hexima.com.au +1 650 452 4684 +61 407 039 983 C O R P ORA T E P R E S ENTA TIO N SLIDE 17